勃林格殷格翰(Boehringer Ingelheim)今天公布了一项为期14周临床2期试验的积极结果。分析显示,其创新醛固酮合成酶抑制剂(ASi)BI 690517与SGLT2抑制剂恩格列净(empagliflozin)联合疗法可显著减少慢性肾病(CKD)患者的蛋白尿水平。 试验分析显...
METHOD. Adults with CKD receiving a maximally tolerated dose of a renin-angiotensin system inhibitor were randomised (R1) 1:1 to receive background EMPA 10 mg or placebo (PBO-EMPA) during an 8-week run-in. They were then re-randomised (R2) 1:1:1:1 to receive BI 690517 (3 mg, 10...
综上所述,醛固酮合成酶抑制剂BI 690517可独立于SGLT2抑制剂发挥降低蛋白尿作用,与恩格列净联用可进一步提升改善蛋白尿效果,且治疗期间患者整体耐受性良好,高钾血症发生情况整体可控。该项研究初步表明,醛固酮合成酶抑制剂是一种有前景的新疗法,与SGLT2抑制剂联合治疗可能会提升对伴或不伴T2DM的CKD患者的治疗疗效,期...
因此,抗癌出身的齐泊腾坦能降尿蛋白也就一点不奇怪了。 正如2023年11月发表在Lancet上的ZENITH-CKD研究,齐泊腾坦可以在达格列净的基础上进一步降低慢性肾脏病患者尿蛋白约30%,反过来达格列净又能减轻齐泊腾坦可能引起的水钠潴留,可谓相得益彰。 从齐泊腾坦到斯巴生坦 斯巴生坦可以在ETA的基础上进一步阻断AT1,有点...
This multinational, randomised, dose-finding, Phase II trial (NCT05182840) investigated the efficacy and safety of BI 690517, given either alone or in combination with empagliflozin (EMPA), in people who had CKD with or without type 2 diabetes (T2D) [1, 2]. Here, we present an analysis ...
We report safety results for BI690517 (vicadrostat), a potent, selective aldosterone synthase inhibitor under investigation for CKD.Four phase 1 studies of BI690517 conducted in healthy European/Chinese/Japanese men: two single rising dose (SRD) and two multiple rising dose (MRD) studies. ...
慢性肾脏病(CKD)已成为全球危害人类健康的重要公共卫生问题,临床亟需更多有效且安全性良好的治疗手段1,2。既往研究表明,醛固酮过量与CKD进展密切相关3。醛固酮合成酶抑制剂可直接减少醛固酮生成,为CKD管理提供了新思路。 近期,在美国肾脏病学会肾脏周(ASN Kidney Week)公布了醛固酮合成酶抑制剂BI 690517的II期研究相关结...